# BPC-157 TB-500 Dosage: What the Research Literature Reports (Research Context)
> BPC-157 TB-500 dosage has no validated basis. Research-context summary of single-compound animal doses, half-life, oral vs injectable routes, and why community loading protocols lack trial support. Cited.
What was given to which species, at which dose, by which route, in the underlying studies. Research context only; no human dose is recommended here.
## BPC-157 TB-500 Dosage in the Research Literature
BPC-157 TB-500 dosage has no validated basis. There is no peer-reviewed combination dose-finding study, no established blend ratio, and no validated human dose for the pair [6][7]. Everything below describes what was administered to which species at which dose in the underlying single-compound studies — it is research context, not human-use guidance, and this page recommends nothing.
Commercial research-product labeling commonly pairs BPC-157 and TB-500 at fixed combined masses per vial — for example ~10 mg plus ~10 mg, or a 20 mg combined vial — but those numbers are product packaging, not a studied dose. In the underlying animal work, the BPC-157 component was frequently dosed per body weight at ~10 µg/kg and ~10 ng/kg, with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats [1]. The TB-500 / Thymosin Beta-4 component spans a wide range — for instance 2-18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study — and 150 µg twice weekly for six months in the mdx muscular-dystrophy study [4]. None of these is a human dose, and none was given as the blend.
The only human reference points come from full-length Thymosin Beta-4, not the TB-500 fragment and not the pair: intravenous Thymosin Beta-4 was reported well tolerated up to 1260 mg in early safety work, and a later first-in-human study used single doses around 25 µg/kg and 5 µg/kg daily for ten days [4][5]. Those are single-agent safety reference points for a different molecule, cited here only to be clear about what human numbers do and do not exist. There is no human BPC-157 TB-500 dose to report, and this page does not construct one.
## Half-life, routes, and the non-monotonic dose-response
### Half-life of BPC-157 and TB-500
BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study. No validated human half-life exists for the TB-500 heptapeptide; human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics [4][5]. No validated half-life exists for the blend.
BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study; no validated human half-life exists for the TB-500 heptapeptide, and none exists for the blend. Human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but that is the full-length protein, not the Ac-LKKTETQ 7-mer [4][5].
The dose-response data carry a specific warning for the 'more is better' loading logic that circulates online. In the rat embolic-stroke study, Thymosin Beta-4 dosing was non-monotonic — a modeled optimum near 3.75 mg/kg, while 18 mg/kg gave no benefit [4]. A higher dose was not a better dose. Routes studied across the single-compound literature include intraperitoneal (predominant in the rodent efficacy work), subcutaneous and intramuscular (the predominant research-community routes, not from controlled human efficacy trials), intravenous (human Phase 1 of full-length Thymosin Beta-4; a BPC-157 IV safety pilot), and local or topical application in individual-compound wound and tendon models.
### Oral vs Injectable Routes for BPC-157 and TB-500 in Studies
BPC-157 is studied as a 'stable gastric' peptide and has been administered perorally in animal work, while the predominant research-community route for the blend is injection [1]. Oral blend products are marketed but lack validated pharmacokinetics; there is no controlled human bioavailability data for an oral BPC 157 TB 500 product.
## Reconstitution, frequency, and cycling — described, not prescribed
### Reconstitution practice for the blend
Research peptides are supplied as lyophilized powder and reconstituted in bacteriostatic or sterile water, then refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [5]. This is described for research handling, not as human-use guidance.
### Injection frequency in the literature
There is no validated injection schedule for the blend. The underlying animal studies used per-body-weight intraperitoneal dosing — BPC-157 around 10 µg/kg, full-length Thymosin Beta-4 in mg/kg ranges [1][4]. Community 'loading then maintenance' protocols have no controlled-trial basis.
### Cycling and 'loading' protocols
Fixed-ratio vials and 'loading then maintenance' cycles circulate in the community but have no basis in controlled human trials. The rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — a high dose gave no benefit [4] — which directly undercuts 'more is better' loading logic.
### What Research-Community Discussion Gets Right and Wrong
Discussion of BPC-157 TB-500 on Reddit and similar forums gets the broad mechanism story roughly right — two repair peptides, angiogenesis, actin — but routinely overstates the evidence, presenting community 'protocols' and dramatic recovery claims as if validated. The published evidence is preclinical, single-compound, and largely from animal models [6][7][8]; no controlled human combination data exist. The reliable parts are the single-compound mechanisms; the unreliable parts are the doses, ratios, and outcome promises.
---
A barely-there evidence ledger of the BPC-157 and TB-500 record — the few single-compound findings that hold set in one tier, the blend-level and access gaps left one tier down and in plain sight, with no clinic behind the page and nothing here dispensed.